0001193125-26-099362
SEC filingCullinan Therapeutics, Inc. reported a net loss of $219.9 million for fiscal year 2025, driven by significant operating expenses of $241.6 million, primarily from research and development ($187.4 million) and general and administrative costs ($54.2 million). The company generated no revenue, resulting in a loss from operations of $241.6 million, partially offset by interest income of $22.2 million. The comprehensive loss attributable to Cullinan was $218.7 million. The balance sheet shows total assets of $448.4 million, with strong liquidity from cash, cash equivalents, and investments totaling $436.2 million. Total liabilities were $39.6 million, resulting in stockholders' equity of $408.7 million. Cash flow from operations was negative $175.8 million, while investing activities provided $180.0 million primarily from maturities of marketable securities. The company ended the year with $98.4 million in cash and cash equivalents. Basic and diluted net loss per share was $37, based on 59.7 million weighted-average shares.
Cullinan Therapeutics, Inc. reported a net loss of $219.9 million for fiscal year 2025, with no revenue generated during the period. The company's loss from operations was $241.6 million, primarily driven by research and development expenses of $187.4 million and general and administrative expenses of $54.2 million. Interest income of $22.2 million partially offset the operating loss. The comprehensive loss attributable to Cullinan was $218.7 million, which includes an unrealized gain on investments of $1.2 million. Basic and diluted net loss per share was $37, calculated using 59.7 million weighted-average shares. The company's accumulated deficit increased to $588.1 million as of December 31, 2025.
No revenue was reported for fiscal year 2025. The company is a clinical-stage biopharmaceutical company focused on developing oncology therapies, and as such, has not yet generated product revenue from commercial sales. The financial statements indicate the company is in the research and development phase, with all financial results reflecting pre-revenue operations. No segment breakdown or geographic revenue mix is disclosed in the provided data, consistent with a company in the development stage without commercialized products.
With no revenue reported, traditional margin calculations (gross margin, operating margin) cannot be derived from the available data. The company's cost structure is dominated by research and development expenses, which accounted for 77.6% of total operating expenses ($187.4 million of $241.6 million). General and administrative expenses represented the remaining 22.4% of operating costs. The company's net loss margin relative to operating expenses shows that interest income reduced the operating loss by approximately 9.2% ($22.2 million interest income relative to $241.6 million operating loss). Equity-based compensation expense of $36.0 million represented a significant non-cash component of the operating expenses.
The company used $175.8 million in cash from operating activities during fiscal year 2025, primarily due to the net loss of $219.9 million, partially offset by non-cash adjustments including equity-based compensation of $36.0 million. Investing activities provided $180.0 million in cash, mainly from maturities of marketable securities ($416.6 million) exceeding purchases of marketable securities ($236.5 million). Financing activities provided $1.1 million from issuance of common stock under equity-based compensation plans. The balance sheet shows strong liquidity with total current assets of $386.8 million, including $88.3 million in cash and cash equivalents and $289.6 million in short-term investments. Total assets were $448.4 million, with total liabilities of $39.6 million, resulting in stockholders' equity of $408.7 million. The company's accumulated deficit stood at $588.1 million as of December 31, 2025.
The filing does not provide specific forward-looking guidance, management projections, or explicit strategic priorities for future periods. As a clinical-stage biopharmaceutical company, Cullinan Therapeutics continues to focus on research and development activities, as evidenced by the $187.4 million spent on R&D during fiscal year 2025. The company's cash position of $98.4 million at year-end, combined with $347.9 million in short-term and long-term investments, provides liquidity to continue operations. Risk factors typical for development-stage biopharmaceutical companies would include clinical trial outcomes, regulatory approvals, competition, and the need for additional financing to achieve commercialization. No specific guidance on future revenue expectations or profitability timelines is disclosed in the provided financial data.